Evidence map›Paper›PMID 40490801›Full record

Trial reportAlzheimer's research & therapy2025

Genetic background and multidomain interventions in mild cognitive impairment.

Kosuke Fujita, Tetsuaki Kimura, Akiko Yamakawa, Shumpei Niida, Kouichi Ozaki, Takashi Sakurai, Hidenori Arai, Daichi Shigemizu, J-MINT study group

Abstract readMulticenter StudyRandomized Controlled Trial
In one paragraph

Trial report in Alzheimer's research & therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Trial
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Kosuke FujitaDepartment of Prevention and Care Science, Research Institute, National Center for Geriatrics and Gerontology, Obu, Aichi, 474-8511, Japan.
Tetsuaki KimuraMedical Genome Center, Research Institute, National Center for Geriatrics and Gerontology, Obu, Aichi, 474-8511, Japan.
Akiko YamakawaMedical Genome Center, Research Institute, National Center for Geriatrics and Gerontology, Obu, Aichi, 474-8511, Japan.
Shumpei NiidaResearch Institute, National Center for Geriatrics and Gerontology, Obu, Aichi, 474-8511, Japan.
Kouichi OzakiMedical Genome Center, Research Institute, National Center for Geriatrics and Gerontology, Obu, Aichi, 474-8511, Japan.
Takashi SakuraiResearch Institute, National Center for Geriatrics and Gerontology, Obu, Aichi, 474-8511, Japan.
Hidenori AraiNational Center for Geriatrics and Gerontology, Obu, Aichi, 474-8511, Japan.
Daichi ShigemizuMedical Genome Center, Research Institute, National Center for Geriatrics and Gerontology, Obu, Aichi, 474-8511, Japan. daichi@ncgg.go.jp.
J-MINT study group

Funding

Japan Agency for Medical Research and Development JP22de0107002, JP23ae0101077, JP23dk0207052, JP18kk0205009, JP21dk0207045 and JP23dk0207060Japan Society for the Promotion of Science 23K21306National Center for Geriatrics and Gerontology 22-23, 24-15, 24-11 and 23-7
6 · The paper itself

Abstract

backgroundThe growing prevalence of dementia emphasizes the need for effective prevention strategies. Although the partial efficacy of multidomain interventions for dementia prevention has been demonstrated, understanding the characteristics of individuals who benefit most from these interventions is crucial for optimizing resource allocation. This study investigated the association between participants' genetic backgrounds and the effectiveness of multidomain interventions for preventing dementia.

methodsThis study utilized data from the Japan-Multimodal Intervention Trial for the Prevention of Dementia (J-MINT), where older adults with mild cognitive impairment underwent 18 months of multidomain intervention. The intervention included exercise, nutrition, cognitive stimulation, social participation, and vascular risk management. Participants who completed the J-MINT intervention and had genetic data, including whole-genome sequencing (WGS), were analyzed. Using Japanese polygenic risk scores (PRSs) for Alzheimer's disease, participants were stratified into high- and low-genetic-risk groups. Cognitive composite score (CPS) improvement rates at 6-, 12-, and 18-months were compared between intervention and control groups, with subgroup analyses performed by age (< 75 and

resultsAmong 289 participants analyzed (168 aged < 75 years; 121 aged ≥ 75 years), 99 were classified into the high-risk PRS group (56 intervention, 43 control) and 190 into the low-risk PRS group (92 intervention, 98 control). For participants aged ≥ 75 years, no statistically significant differences in CPS improvement rates were observed between the intervention and control groups, regardless of PRS classification. However, in participants aged < 75, those in the high-risk PRS group showed significant CPS improvement at the 6-month follow-up. Additionally, analysis of 9,978,605 genetic variants identified two loci, ID3 and LMO1 (rs2067053 and rs201082658), with suggestive associations (P < 1 × 10⁻

conclusionsThis study highlighted the utility of PRS in predicting cognitive improvement following multidomain interventions and identified genetic variants that may influence the intervention's effectiveness. The findings provide a valuable foundation for personalized dementia prevention strategies.

Indexed as

Cognitive DysfunctionAgedAged, 80 and overCombined Modality TherapyFemaleHumansJapanMaleWhole Genome SequencingAlzheimer’s diseaseClinical trialDementiaMCIPolygenic risk score

Identifiers

PMID40490801
PMCPMC12150445

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.